Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did not get the vaccine. View on euronews ...

LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...

Add Yahoo as a preferred source to see more of our stories on Google. With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The ...

LIBERTY is a Phase 3, randomized, double-blind clinical trial to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and ...

The mass-produced COVID-19 vaccines built using the mRNA model – which were rapidly manufactured during the global pandemic – could also help the immune system recognise and attack cancer tumours, new ...

The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...

WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...

Holding meds does not enhance humoral immunogenicity and is associated with disease flares for patients with inflammatory arthritis.

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we ...